Breast Implant Research Bill Seeks CDRH Postmarket Reports To Congress
This article was originally published in The Gray Sheet
Executive Summary
Regular updates to Congress from FDA on the status of postmarket evaluations of saline breast implant data would be required under HR 1961, a bill introduced by Reps. Roy Blunt (R-Mo.) and Gene Green (D-Texas) May 23.
You may also be interested in...
GAO Oversight Of FDA Performance Included In House Device User Fee Bill
FDA's ability to achieve timely review of premarket applications will be closely monitored by Congress and industry if the agency implements a planned medical device user fee program
GAO Oversight Of FDA Performance Included In House Device User Fee Bill
FDA's ability to achieve timely review of premarket applications will be closely monitored by Congress and industry if the agency implements a planned medical device user fee program
Energy & Commerce Looking To Include Breast Implant Bill In Device Package
The House Energy & Commerce/Oversight & Investigations Subcommittee is requesting that FDA deliver all documents related to a criminal investigation of Mentor by Oct. 9